Professional Summary »
Specializing In »
Practice Locations »
Patient Ratings »
Referring Physicians »
Specializing In
- Anal and Rectal Cancer
- Desmoid Tumor
- Genitourinary Cancer
- Head and Neck Cancer
Biography
Alexander Chin, MD, MBA, is a radiation oncologist with Stanford Medicine Cancer Center and a clinical assistant professor in the Department of Radiation Oncology with the Stanford School of Medicine. He also serves as Director of Market Development for Stanford Health Care, acting as a liaison between faculty leadership and hospital administration, to advance Stanford Medicine’s mission of providing compassionate leading-edge care to the communities that we serve.
Dr. Chin is committed to ensuring the delivery of care of the highest quality and value. He provides clinical expertise in diagnosing and treating the full range of cancers, including those of the lung, breast, and central nervous system. In addition, he serves on national leadership teams formed to advance the practice of cancer care. Dr. Chin is currently a member of the Payment Reform Task Force for the American Society of Clinical Oncology and has previously served on their Clinical Practice Committee and as a health policy fellow. He was one of just two oncologists in the US selected to participate in a year-long program on policy leadership.
He currently serves on the Stanford Cancer Network Quality Committee. This team develops and implements our care delivery standards, strategies, and metrics to ensure consistently excellent cancer care from all Stanford Health Care providers in all locations.
Dr. Chin has conducted extensive research and published his findings in numerous peer-reviewed journals. Topics range from novel oncology payment models to the use of new imaging parameters in lung cancer. His scholarship appears in Cancer, JCO Oncology Practice, Clinical Lung Cancer, International Journal of Radiation Oncology, Biology, Physics, and elsewhere.
He has made presentations on stereotactic body radiotherapy (SBRT) and other treatment advances at meetings of the Radiological Society of North America and American Society for Radiation Oncology. He also has addressed these topics as an invited lecturer in training sessions for oncology residents.
He has won numerous awards, including recognition for his research from the Radiological Society of North America. He also has earned honors from the American Society of Clinical Oncology and from his alma maters: the Perelman School of Medicine at the University of Pennsylvania as well as Wharton and Yale.
Dr. Chin earned a Bachelor of Science degree in molecular biophysics and biochemistry from Yale University. He earned his medical degree from Perelman School of Medicine at the University of Pennsylvania, and his MBA at the Wharton School. He completed his residency in Radiation Oncology at Stanford Health Care.
He is a member of the Radiological Society of North America, American Society for Radiation Oncology, and American Society for Clinical Oncology.
Dr. Chin is committed to ensuring the delivery of care of the highest quality and value. He provides clinical expertise in diagnosing and treating the full range of cancers, including those of the lung, breast, and central nervous system. In addition, he serves on national leadership teams formed to advance the practice of cancer care. Dr. Chin is currently a member of the Payment Reform Task Force for the American Society of Clinical Oncology and has previously served on their Clinical Practice Committee and as a health policy fellow. He was one of just two oncologists in the US selected to participate in a year-long program on policy leadership.
He currently serves on the Stanford Cancer Network Quality Committee. This team develops and implements our care delivery standards, strategies, and metrics to ensure consistently excellent cancer care from all Stanford Health Care providers in all locations.
Dr. Chin has conducted extensive research and published his findings in numerous peer-reviewed journals. Topics range from novel oncology payment models to the use of new imaging parameters in lung cancer. His scholarship appears in Cancer, JCO Oncology Practice, Clinical Lung Cancer, International Journal of Radiation Oncology, Biology, Physics, and elsewhere.
He has made presentations on stereotactic body radiotherapy (SBRT) and other treatment advances at meetings of the Radiological Society of North America and American Society for Radiation Oncology. He also has addressed these topics as an invited lecturer in training sessions for oncology residents.
He has won numerous awards, including recognition for his research from the Radiological Society of North America. He also has earned honors from the American Society of Clinical Oncology and from his alma maters: the Perelman School of Medicine at the University of Pennsylvania as well as Wharton and Yale.
Dr. Chin earned a Bachelor of Science degree in molecular biophysics and biochemistry from Yale University. He earned his medical degree from Perelman School of Medicine at the University of Pennsylvania, and his MBA at the Wharton School. He completed his residency in Radiation Oncology at Stanford Health Care.
He is a member of the Radiological Society of North America, American Society for Radiation Oncology, and American Society for Clinical Oncology.
View Full Biography »
Professional Summary
Education & Certifications
- Board Certification: American Board of Radiology, Radiation Oncology (2021)
- Residency: Stanford University Radiation Oncology Residency (2019) CA
- Internship: Santa Clara Valley Medical Center Internal Medicine Residency (2015) CA
- Medical Education: Perelman School of Medicine University of Pennsylvania (2014) PA
- MD, University of Pennsylvania School of Medicine (2014)
- MBA, The Wharton School, Health Care Management (2014)
- BS, Yale University, Molecular Biophysics & Biochemistry (2009)
Memberships
- Member, Coverage & Reimbursement Steering Group, American Society of Clinical Oncology (2022 - Present)
- Member, Clinical Practice Committee, American Society of Clinical Oncology (2018 - 2019)
- Health Policy Fellow, American Society of Clinical Oncology (2017 - 2018)
Administrative Appointments
- Director of Market Development, Stanford Health Care (2019 - Present)
Publications
-
Feasibility and limitations of bulk density assignment in MRI for head and neck IMRT treatment planning.
Chin, A. L., Lin, A., Anamalayil, S., & Teo, B.-K. K. (2014). Feasibility and limitations of bulk density assignment in MRI for head and neck IMRT treatment planning. Journal of Applied Clinical Medical Physics, 15(5), 4851-? -
Quality, and not Just Quantity, of Education Accounts for Differences in Psychometric Performance between African Americans and White Non-Hispanics with Alzheimer's Disease
Chin, A. L., Negash, S., Xie, S., Arnold, S. E., & Hamilton, R. (2012). Quality, and not Just Quantity, of Education Accounts for Differences in Psychometric Performance between African Americans and White Non-Hispanics with Alzheimer's Disease. JOURNAL OF THE INTERNATIONAL NEUROPSYCHOLOGICAL SOCIETY, 18(2), 277–285. -
The role of mechanical forces and adenosine in the regulation of intestinal enterochromaffin cell serotonin secretion
Chin, A., Svejda, B., Gustafsson, B. I., Granlund, A. B., Sandvik, A. K., TIMBERLAKE, A., … Kidd, M. (2012). The role of mechanical forces and adenosine in the regulation of intestinal enterochromaffin cell serotonin secretion. AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY, 302(3), G397–G405. -
Diversity and Disparity in Dementia: The Impact of Ethnoracial Differences in Alzheimer Disease
Chin, A. L., Negash, S., & Hamilton, R. (2011). Diversity and Disparity in Dementia: The Impact of Ethnoracial Differences in Alzheimer Disease. ALZHEIMER DISEASE & ASSOCIATED DISORDERS, 25(3), 187–195. -
Patterns of Care in Adjuvant Therapy for Resected Oral Cavity Squamous Cell Cancer in Elderly Patients.
Pollom, E. L., Chin, A. L., Lee, N. Y., & Tsai, C. J. (2017). Patterns of Care in Adjuvant Therapy for Resected Oral Cavity Squamous Cell Cancer in Elderly Patients. International Journal of Radiation Oncology, Biology, Physics. -
Normal Tissue Constraints for Abdominal and Thoracic Stereotactic Body Radiotherapy.
Pollom, E. L., Chin, A. L., Diehn, M., Loo, B. W., & Chang, D. T. (2017). Normal Tissue Constraints for Abdominal and Thoracic Stereotactic Body Radiotherapy. Seminars in Radiation Oncology, 27(3), 197–208. -
Cost-Effectiveness of Radiation and Chemotherapy for High-Risk Low-Grade Glioma.
Qian, Y., Maruyama, S., Kim, H., Pollom, E. L., Kumar, K. A., Chin, A. L., … Soltys, S. G. (2017). Cost-Effectiveness of Radiation and Chemotherapy for High-Risk Low-Grade Glioma. Neuro-Oncology. -
Impact of Intensity-Modulated Radiotherapy on Health Care Costs of Patients With Anal Squamous Cell Carcinoma.
Chin, A. L., Pollom, E. L., Qian, Y., Koong, A. C., & Chang, D. T. (2017). Impact of Intensity-Modulated Radiotherapy on Health Care Costs of Patients With Anal Squamous Cell Carcinoma. Journal of Oncology Practice, JOP2017024810. -
Nonoperative Management of Rectal Cancer: A Modern Perspective.
Qian, Y., Chin, A. L., Toesca, D. A., Koong, A. C., & Chang, D. T. (2017). Nonoperative Management of Rectal Cancer: A Modern Perspective. Oncology (Williston Park, N.Y.), 31(10), e13–e22. -
Survival Impact of Postoperative Radiotherapy Timing in Pediatric and Adolescent Medulloblastoma.
Chin, A. L., Moding, E. J., Donaldson, S. S., Gibbs, I. C., Soltys, S. G., Hiniker, S. M., & Pollom, E. L. (2018). Survival Impact of Postoperative Radiotherapy Timing in Pediatric and Adolescent Medulloblastoma. Neuro-Oncology. -
Prognostic Value of Pretreatment FDG-PET Parameters in High-dose Image-guided Radiotherapy for Oligometastatic Non-Small-cell Lung Cancer.
Chin, A. L., Kumar, K. A., Guo, H. H., Maxim, P. G., Wakelee, H., Neal, J. W., … Gensheimer, M. F. (2018). Prognostic Value of Pretreatment FDG-PET Parameters in High-dose Image-guided Radiotherapy for Oligometastatic Non-Small-cell Lung Cancer. Clinical Lung Cancer. -
Cost Effectiveness of Radiation and Chemotherapy for High-Risk Low Grade Glioma
Qian, Y., Maruyama, S., Kim, H., Pollom, E. L., Kumar, K. A., Harris, J. P., … Soltys, S. G. (2018). Cost Effectiveness of Radiation and Chemotherapy for High-Risk Low Grade Glioma. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS. ELSEVIER SCIENCE INC. -
Rising rates of bilateral mastectomy with reconstruction following neoadjuvant chemotherapy.
Pollom, E. L., Qian, Y., Chin, A. L., Dirbas, F. M., Asch, S. M., Kurian, A. W., … Tsai, C. J. (2018). Rising rates of bilateral mastectomy with reconstruction following neoadjuvant chemotherapy. International Journal of Cancer. -
The role of bone marrow and spleen irradiation in the development of acute hematologic toxicity during chemoradiation for esophageal cancer.
Chin, A. L., Aggarwal, S., Pradhan, P., Bush, K., von Eyben, R., Koong, A. C., & Chang, D. T. (2018). The role of bone marrow and spleen irradiation in the development of acute hematologic toxicity during chemoradiation for esophageal cancer. Advances in Radiation Oncology, 3(3), 297–304. -
Long-Term Update of Stereotactic Radiosurgery for Benign Spinal Tumors.
Chin, A. L., Fujimoto, D., Kumar, K. A., Tupper, L., Mansour, S., Chang, S. D., … Soltys, S. G. (2018). Long-Term Update of Stereotactic Radiosurgery for Benign Spinal Tumors. Neurosurgery. -
Prognostic Significance of P16 Expression and P53 Expression in Primary Vaginal Cancer.
Nwachukwu, C. R., Harris, J. P., Chin, A., Von Eyben, R., Giaretta, S., Shaffer, J. L., … Kidd, E. A. (2018). Prognostic Significance of P16 Expression and P53 Expression in Primary Vaginal Cancer. International Journal of Gynecological Pathology : Official Journal of the International Society of Gynecological Pathologists. -
The impact of state parity laws on copayments for and adherence to oral endocrine therapy for breast cancer.
Chin, A. L., Bentley, J. P., & Pollom, E. L. (2018). The impact of state parity laws on copayments for and adherence to oral endocrine therapy for breast cancer. Cancer. -
Sinoatrial node dysfunction after stereotactic ablative radiation therapy in the chest
Qian, Y., Dudley, S. A., Kumar, K., Chaudhuri, A., Chin, A., Harris, J. P., … Loo, B. W. (2017). Sinoatrial node dysfunction after stereotactic ablative radiation therapy in the chest. JOURNAL OF CLINICAL ONCOLOGY. AMER SOC CLINICAL ONCOLOGY. -
Survival impact of postoperative radiotherapy timing in pediatric and adolescent medulloblastoma
Chin, A. L., Moding, E. J., Donaldson, S. S., Gibbs, I. C., Soltys, S. G., Hiniker, S. M., & Pollom, E. L. (2018). Survival impact of postoperative radiotherapy timing in pediatric and adolescent medulloblastoma. NEURO-ONCOLOGY, 20(8), 1133–41. -
Prognostic Value of Pretreatment FDG-PET Parameters in High-dose Image-guided Radiotherapy for Oligometastatic Non-Small-cell Lung Cancer
Chin, A. L., Kumar, K. A., Guo, H. H., Maxim, P. G., Wakelee, H., Neal, J. W., … Gensheimer, M. F. (2018). Prognostic Value of Pretreatment FDG-PET Parameters in High-dose Image-guided Radiotherapy for Oligometastatic Non-Small-cell Lung Cancer. CLINICAL LUNG CANCER, 19(5), E581–E588. -
The impact of state parity laws on copayments for and adherence to oral endocrine therapy for breast cancer
Chin, A. L., Bentley, J. P., & Pollom, E. L. (2019). The impact of state parity laws on copayments for and adherence to oral endocrine therapy for breast cancer. CANCER, 125(3), 374–81. -
Rising rates of bilateral mastectomy with reconstruction following neoadjuvant chemotherapy
Pollom, E. L., Qian, Y., Chin, A. L., Dirbas, F. M., Asch, S. M., Kurian, A. W., … Tsai, C. J. (2018). Rising rates of bilateral mastectomy with reconstruction following neoadjuvant chemotherapy. INTERNATIONAL JOURNAL OF CANCER, 143(12), 3262–72. -
Application of pharmacoeconomics to formulary management in a health system setting.
Studdert, A. L., Gong, C. L., Srinivas, S., Chin, A. L., & Deresinski, S. (2019). Application of pharmacoeconomics to formulary management in a health system setting. American Journal of Health-System Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists, 76(6), 381–386. -
Prognostic Significance of P16 Expression and P53 Expression in Primary Vaginal Cancer.
Nwachukwu, C. R., Harris, J. P., Chin, A., Von Eyben, R., Giaretta, S., Shaffer, J. L., … Kidd, E. A. (2019). Prognostic Significance of P16 Expression and P53 Expression in Primary Vaginal Cancer. International Journal of Gynecological Pathology : Official Journal of the International Society of Gynecological Pathologists, 38(6), 588–96. -
Long-Term Update of Stereotactic Radiosurgery for Benign Spinal Tumors
Chin, A. L., Fujimoto, D., Kumar, K. A., Tupper, L., Mansour, S., Chang, S. D., … Soltys, S. G. (2019). Long-Term Update of Stereotactic Radiosurgery for Benign Spinal Tumors. NEUROSURGERY, 85(5), 708–16. -
Updates to the ASCO Patient-Centered Oncology Payment Model.
Ward, J. C., Bourbeau, B. R., Chin, A. L., Page, R. D., Grubbs, S. S., Kamin, D. Y., … Rappaport, M. (2020). Updates to the ASCO Patient-Centered Oncology Payment Model. JCO Oncology Practice, JOP1900776. -
Stereotactic Radiosurgery After Resection of Brain Metastases: Changing Patterns of Care in the United States.
Chin, A. L., Li, G., Gephart, M. H., Sandhu, N., Nagpal, S., Soltys, S. G., & Pollom, E. L. (2020). Stereotactic Radiosurgery After Resection of Brain Metastases: Changing Patterns of Care in the United States. World Neurosurgery. -
Pulmonary Hemorrhage in Patients Treated with Thoracic Stereotactic Ablative Radiotherapy and Anti-Angiogenic Agents
Lau, B., No, H., (Fred) Wu, Y., Devine, M., Ko, R., Loo, B., … Vitzthum, L. (2021). Pulmonary Hemorrhage in Patients Treated with Thoracic Stereotactic Ablative Radiotherapy and Anti-Angiogenic Agents. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS. LIPPINCOTT WILLIAMS & WILKINS. -
Treatment Patterns for Isolated Nodal Recurrences in Non-Small Cell Lung Cancer After Definitive Stereotactic Ablative Radiotherapy
No, H., Devine, M., Lau, B., Loo, B., Diehn, M., Chin, A., & Vitzthum, L. (2021). Treatment Patterns for Isolated Nodal Recurrences in Non-Small Cell Lung Cancer After Definitive Stereotactic Ablative Radiotherapy. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS. LIPPINCOTT WILLIAMS & WILKINS. -
Pulmonary Hemorrhage in Patients Treated With Thoracic Stereotactic Ablative Radiotherapy and Anti-Angiogenic Agents
Lau, B., No, H. J., Wu, Y. F., Ko, R. B., Devine, M., Das, M., … Vitzthum, L. (2021). Pulmonary Hemorrhage in Patients Treated With Thoracic Stereotactic Ablative Radiotherapy and Anti-Angiogenic Agents. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS. ELSEVIER SCIENCE INC. -
IMRT and SBRT Treatment Planning Study for the First Clinical Biology-Guided Radiotherapy System.
Pham, D., Simiele, E., Breitkreutz, D., Capaldi, D., Han, B., Surucu, M., … Kovalchuk, N. (2022). IMRT and SBRT Treatment Planning Study for the First Clinical Biology-Guided Radiotherapy System. Technology in Cancer Research & Treatment, 21, 15330338221100231. -
Local control outcomes using stereotactic body radiotherapy or surgical resection for metastatic sarcoma.
Gutkin, P. M., von Eyben, R., Chin, A., Donaldson, S. S., Oh, J., Jiang, A., … Hiniker, S. M. (2022). Local control outcomes using stereotactic body radiotherapy or surgical resection for metastatic sarcoma. International Journal of Radiation Oncology, Biology, Physics. -
Characterization of Metastatic Non-Small Cell Lung Cancer and Oligometastatic Incidence in an Era of Changing Treatment Paradigms.
No, H. J., Raja, N., Von Eyben, R., Das, M., Roy, M., Myall, N., … Vitzthum, L. K. (2022). Characterization of Metastatic Non-Small Cell Lung Cancer and Oligometastatic Incidence in an Era of Changing Treatment Paradigms. International Journal of Radiation Oncology, Biology, Physics. -
Isolated Nodal Recurrence After Definitive Stereotactic Ablative Radiotherapy for Non-Small Cell Lung Cancer.
Devine, M., Merriott, D. J., No, H. J., Lau, B., Say, C., Yoo, C., … Vitzthum, L. K. (2022). Isolated Nodal Recurrence After Definitive Stereotactic Ablative Radiotherapy for Non-Small Cell Lung Cancer. Practical Radiation Oncology. -
Early Outcomes and Toxicity with Concurrent Chemotherapy and Hypofractionated Radiation Therapy in Patients with Non-Small Cell Lung Cancer
Hui, C., Marquez, C., Lau, B., Von Eyben, R., Das, M., Myall, N., … Vitzthum, L. (2022). Early Outcomes and Toxicity with Concurrent Chemotherapy and Hypofractionated Radiation Therapy in Patients with Non-Small Cell Lung Cancer. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS. LIPPINCOTT WILLIAMS & WILKINS. -
Dosimetric Predictors of Local Control after Stereotactic Ablative Radiotherapy (SABR) for Lung Tumors: A Secondary Analysis of a Phase II Prospective Trial of Individualized SABR (iSABR)
Wu, Y. F., Lau, B., Fu, J., Skinner, L., Gensheimer, M., Gee, H., … Vitzthum, L. (2022). Dosimetric Predictors of Local Control after Stereotactic Ablative Radiotherapy (SABR) for Lung Tumors: A Secondary Analysis of a Phase II Prospective Trial of Individualized SABR (iSABR). AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS. LIPPINCOTT WILLIAMS & WILKINS. -
Diagnostic CT Planning for Palliative Inpatient Treatments: A Cost-savings and Clinical Analysis of a Pilot Program to Reduce the Need for CT Simulation Scans
Blomain, E., Alnajjar, N., Chin, A., Lewis, J., Kovalchuk, N., & Horst, K. (2022). Diagnostic CT Planning for Palliative Inpatient Treatments: A Cost-savings and Clinical Analysis of a Pilot Program to Reduce the Need for CT Simulation Scans. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS. LIPPINCOTT WILLIAMS & WILKINS. -
Real-world risk of brain metastases in stage III non-small cell lung cancer in the era of PET and MRI staging.
Alhusaini, S., Lanman, T. A., Ko, R. B., Therkelsen, K. E., Eyben, R. V., Diehn, M., … Nagpal, S. (2023). Real-world risk of brain metastases in stage III non-small cell lung cancer in the era of PET and MRI staging. Frontiers in Oncology, 13, 1139940. -
Pulmonary Hemorrhage in Patients Treated with Thoracic Stereotactic Ablative Radiotherapy and Anti-Angiogenic Agents.
Lau, B., Wu, Y. F., No, H. J., Ko, R. B., Devine, M., Das, M. S., … Vitzthum, L. K. (2023). Pulmonary Hemorrhage in Patients Treated with Thoracic Stereotactic Ablative Radiotherapy and Anti-Angiogenic Agents. Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer. -
Unilateral diaphragmatic paralysis after stereotactic ablative radiotherapy to a lung tumor abutting the course of the phrenic nerve.
Eke, I., Guo, H. H., Loo, J. B., Sung, A. W., Diehn, M., Vitzthum, L., … Gensheimer, M. F. (2023). Unilateral diaphragmatic paralysis after stereotactic ablative radiotherapy to a lung tumor abutting the course of the phrenic nerve. Practical Radiation Oncology. -
Individualized Stereotactic Ablative Radiotherapy for Lung Tumors: The iSABR Phase 2 Nonrandomized Controlled Trial.
Gensheimer, M. F., Gee, H., Shirato, H., Taguchi, H., Snyder, J. M., Chin, A. L., … Diehn, M. (2023). Individualized Stereotactic Ablative Radiotherapy for Lung Tumors: The iSABR Phase 2 Nonrandomized Controlled Trial. JAMA Oncology. -
Patterns of local recurrence and risk of skin recurrence in soft tissue sarcomas after surgical resection.
Ewongwo, A., Oladipo, E. D., Hui, C., Avedian, R. S., Steffner, R. J., Mohler, D. G., … Moding, E. J. (2023). Patterns of local recurrence and risk of skin recurrence in soft tissue sarcomas after surgical resection. Practical Radiation Oncology. -
Personalized Accelerated ChEmoRadiation (PACER) for Lung Cancer: Protocol for a Bayesian Optimal Phase I/II Trial.
Hui, C., Brown, E., Wong, S., Das, M., Wakelee, H., Neal, J., … Vitzthum, L. K. (2023). Personalized Accelerated ChEmoRadiation (PACER) for Lung Cancer: Protocol for a Bayesian Optimal Phase I/II Trial. Clinical Lung Cancer. -
Patient Selection and Outcomes for Hypofractionated Accelerated Radiation and Concurrent Chemotherapy for Non-Small-Cell Lung Cancer.
Hui, C., Marquez, C., Lau, B., Das, M., Myall, N. J., Roy, M., … Vitzthum, L. K. (2023). Patient Selection and Outcomes for Hypofractionated Accelerated Radiation and Concurrent Chemotherapy for Non-Small-Cell Lung Cancer. Clinical Lung Cancer. -
Predicting Adverse Cardiac Events After Radiotherapy for Locally Advanced Non-Small Cell Lung Cancer.
No, H. J., Guo, F. B., Park, N. J.-I., Kastelowitz, N., Rhee, J.-W. W., Clark, D. E., … Binkley, M. S. (2023). Predicting Adverse Cardiac Events After Radiotherapy for Locally Advanced Non-Small Cell Lung Cancer. JACC. CardioOncology, 5(6), 775–787. -
Intra- and post-pandemic impact of the COVID-19 outbreak on Stanford Health Care.
Phongpreecha, T., Berson, E., Xue, L., Shome, S., Saarunya, G., Fralick, J., … Kerr, A. (2024). Intra- and post-pandemic impact of the COVID-19 outbreak on Stanford Health Care. Academic Pathology, 11(2), 100113.
Practice Locations
Radiation Oncology at Blake Wilbur Building Palo Alto, CA
Palo Alto, CA
Radiation Oncology at Blake Wilbur Building
875 Blake Wilbur Drive
Palo Alto , CA 94304
Make An Appointment More Clinic Information » Getting Here »Thoracic Cancer Program in Palo Alto Palo Alto, CA
Palo Alto, CA
Thoracic Cancer Program in Palo Alto
875 Blake Wilbur Drive
Palo Alto , CA 94304
Make An Appointment More Clinic Information » Getting Here »Sarcoma Program at Blake Wilbur Building Palo Alto, CA
Palo Alto, CA
Sarcoma Program at Blake Wilbur Building
875 Blake Wilbur Drive
Palo Alto , CA 94304
Make An Appointment More Clinic Information » Getting Here »CyberKnife Stereotactic Radiosurgery Program at 875 Blake Wilbur Palo Alto, CA
Palo Alto, CA
CyberKnife Stereotactic Radiosurgery Program at 875 Blake Wilbur
875 Blake Wilbur Drive
Palo Alto , CA 94304
Make An Appointment More Clinic Information » Getting Here »Important Information about Our Organizations and Physician Affiliation
Stanford Health Care, Stanford Health Care Tri-Valley, and Stanford Medicine Partners are each independent nonprofit organizations that are affiliated with but separate from each other and from Stanford University. The physicians who provide care at facilities operated by Stanford Health Care, Stanford Health Care Tri-Valley, and Stanford Medicine Partners are faculty, foundation, or community physicians who are not employees, representatives, or agents of Stanford Health Care, Stanford Health Care Tri- Valley, or Stanford Medicine Partners. Stanford Health Care, Stanford Health Care Tri-Valley, and Stanford Medicine Partners do not exercise control over the care provided by such faculty, foundation, and community physicians and are not responsible for their actions.
Patient Reviews
(35 reviews)
Very compassionate.
Dr. Chin is incredible! I feel so fortunate to have him as my doctor!
He was thoroughly
Thank you and your colleague for the time you gave to us and explained the diagnosis and treatment.
He seems like a good doctor. I am happy he is my doctor!
Very nice doctor
Very good
Dr. Chin is extremely knowledgeable and provided any and allm information relative to my problem!!
Very through docto. Does not leave anything u answered and addresses the tiniest discrepancy possible
Dr Chin and staff provide excellent professional care. He is sensitive to the concerns of his patients and we are beyond grateful for all he has done for me.
Great visit
Awesome and informative
Professional empathetic very competent
Team —answered all questions
Nice doctor
Great doctor
Very knowledgeable, showed concern for patient
Very professional and to the point
Dr. Chen has always been able to communicate with me and share Laymans terms my process of radiation the type of cancer that I had the process he’s made me feel so comfortable and I am extremely grateful for him and his staff in Stanford hospital for the wonderful care I’ve received!
The Dr.'s are all wonderful right along with the receptionist. Everyone I've come into contact with is outstanding. Even phone calls are wonderful.
Very enthusiastic and informative. Really professional doctor
Dr. Chin is friendly, responsive, and takes the time to explain CT results and answers questions whenever I have them. He summarizes the "things to do" at the end of the call and that is helpful. I trust him completely.
Dr. Chin was very prepared to discuss my case and provided a very thorough explanation of his proposed treatment with an explanation of the timing, steps required prior to the radiation and all possible outcomes.
Left with the impression that I was going to be treated with the very best possible care, thoroughness and expertise possible.
I believe that the care that Dr. Chin gives me is of the highest quality!
A very good Doctor
I am impressed by the humble, humane and professional approach of the team
Doctor Chin was kind and listened to my concerns and answered my questions clearly and understandably. I am confident I am getting great care from him and his team.
He was very patient in explaining to my my health and the treatment. So knowledgeable and talking to him i feel that i will be in good hands
Wonderful at explaining treatment and care
Very pleasant dealing with Dr. Alexander Chin
Dr. Chin is very professional and I am confident in his care.
He is great.
I appreciated his respectful and direct manner!
Dr.Chin was very professional and helpful.
She was on-point, clearly answered all of our questions, and offered encouraging thoughts for our recovery.
He and his staff are very friendly and personable and explained clearly what I could expect next. All doctors are working together in a way that I’m not left wondering what’s next
View More »
Referring Physicians
PHYSICIAN HELPLINE
Phone: 1-866-742-4811
Fax: 650-320-9443
Monday–Friday, 8 a.m.–5 p.m.
Fax: 650-320-9443
Monday–Friday, 8 a.m.–5 p.m.
Stanford Health Care provides comprehensive services to refer and track patients, as well as the latest information and news for physicians and office staff. For help with all referral needs and questions, visit Referral Information.
You may also submit a web referral or complete a referral form and fax it to 650-320-9443 or email the Referral Center at ReferralCenter@stanfordhealthcare.org.
- Send referrals online
- Place radiology and lab orders
- View referral status
- Access medical records